IL6 and metabolic syndrome: In the context of COVID-19, a cytokine storm—characterized by elevated interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP)—has been proposed as a contributing factor to dyslipidemia.